Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Deffered Revenue (2016 - 2025)

Tg Therapeutics has reported Non-Current Deffered Revenue over the past 10 years, most recently at $8.8 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $8.8 million for Q4 2025, down 27.12% from a year ago — trailing twelve months through Dec 2025 was $8.8 million (down 27.12% YoY), and the annual figure for FY2025 was $8.8 million, down 27.12%.
  • Non-Current Deffered Revenue for Q4 2025 was $8.8 million at Tg Therapeutics, up from $8.3 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for TGTX hit a ceiling of $16.2 million in Q3 2024 and a floor of $190000.0 in Q3 2023.
  • Median Non-Current Deffered Revenue over the past 5 years was $552000.0 (2021), compared with a mean of $3.5 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: skyrocketed 8408.42% in 2024 and later tumbled 55.46% in 2025.
  • Tg Therapeutics' Non-Current Deffered Revenue stood at $457000.0 in 2021, then crashed by 33.26% to $305000.0 in 2022, then skyrocketed by 1872.46% to $6.0 million in 2023, then soared by 100.88% to $12.1 million in 2024, then fell by 27.12% to $8.8 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $8.8 million (Q4 2025), $8.3 million (Q3 2025), and $1.7 million (Q2 2025) per Business Quant data.